Viking (VKTX) Q3 2026 Earnings Call Transcript
On its Q3 2026 earnings call, Viking Therapeutics discussed its obesity drug VK2735 showing up to 22% weight loss with less frequent dosing schedules.
fool.com ·
Supported Assets
Open Mo
Viking Therapeutics
24/7
-
-over selected period
-since US close
- Last close
- $26.09
- Premium / discount
- -
Updated Reference Yahoo Finance ·
Price differences before fees and execution costs. Compare prices
News
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Trial Progress
Viking Therapeutics reported a third quarter 2026 net loss of $183.2 million and confirmed that enrollment is complete in its VK2735 injectable clinical trials.
tradingview.com ·
Token
- Token
- VKTXc
- Shares per token
- 1.00000000 VKTX